Acromegaly
Welcome,         Profile    Billing    Logout  
 24 Companies   9 Products   9 Products   6 Mechanisms of Action   50 Trials   3648 News 


«12...2324252627282930313233...5960»
  • ||||||||||  Retrospective data, Journal:  The Evaluation of Breast Findings Detected Through Different Visualisation Techniques in Acromegaly Patients- A Retrospective Study. (Pubmed Central) -  Jan 4, 2022   
    Benign and malign breast lesions were found out to be similar to the control group, although breast density rate was detected to be higher in acromegaly patients. A regular follow-up is required in these patients via suitable breast visualization techniques considering their age and clinical status due to mass formation risk derived from increased GH level and extreme breast density despite the absence of any detected breast lesion frequency in acromegaly patients.
  • ||||||||||  Clinical, Journal:  International Multicenter Validation Study of the SAGIT ® Instrument in Acromegaly. (Pubmed Central) -  Dec 30, 2021   
    The research methods and analyses utilized in this study will be useful for simulating the dosages and therapeutic effects of drugs for acromegaly, and will facilitate the research and development of novel therapeutic agents with similar modes of action. The SAGIT instrument is a valid and sensitive tool to comprehensively and accurately assess acromegaly severity.
  • ||||||||||  Clinical, Journal:  Prevalence of comorbidities and associated factors in acromegaly patients in the Turkish population. (Pubmed Central) -  Dec 25, 2021   
    GH normalization after treatment is beneficial for short-term erectile function recovery. In this study, we revealed that the most common comorbidities in acromegaly patients in the Turkish population are thyroid nodules, low HDL-C level, hypertriglyceridemia, HT, colonic polyps, DM and prediabetes, and female gender and age at diagnosis are the most important factors associated with comorbidities.
  • ||||||||||  Tepezza (teprotumumab) / Horizon Therapeutics, Roche
    Review, Journal:  Insulin-Like Growth Factor Pathway and the Thyroid. (Pubmed Central) -  Dec 23, 2021   
    Based on those findings, the development of teprotumumab, a β-arrestin biased agonist as a therapeutic has resulted in the first medication approved by the US FDA for the treatment of TAO. Teprotumumab is now in wide clinical use in North America.
  • ||||||||||  Review, Journal:  The Interaction of Insulin and Pituitary Hormone Syndromes. (Pubmed Central) -  Dec 21, 2021   
    Therefore glucose metabolism needs to be closely monitored and treated in patients with pituitary adenomas. Correction of the pituitary dysfunction is frequently followed by improvement of glucose homeostasis.
  • ||||||||||  Sandostatin LAR Depot (octreotide acetate) / Novartis
    Clinical, Journal:  Disease and Treatment-Related Burden in Patients With Acromegaly Who Are Biochemically Controlled on Injectable Somatostatin Receptor Ligands. (Pubmed Central) -  Dec 18, 2021   
    Patients included in this analysis were enrolled in a randomized phase 3 study, were biochemically-controlled (an IGF-1 < 1.3 × the upper limit of normal [ULN] and average GH < 2.5 ng/ml) and receiving SRL injections for ≥6 months with a stable dose of either long-acting octreotide or lanreotide monotherapy for ≥4 months...GI side effects and ISRs were also common. This study highlights the significant disease burden that still persists for patients with acromegaly that have achieved biochemical control with the use of injectable SRLs.
  • ||||||||||  isotretinoin oral / Generic mfg.
    Journal:  Secondary hypertriglyceridemia. (Pubmed Central) -  Dec 18, 2021   
    Other causes less frequent are endocrinological diseases such as Cushing's syndrome, acromegaly, hypothyroidism; pregnancy, lipodystrophies and autoimmune diseases. Lastly, the identifications and treatment or correction of secondary causes is a corner stone in the treatment of this disease.
  • ||||||||||  Clinical, Journal:  Prevalence of Comorbidities among Patients with Acromegaly. (Pubmed Central) -  Dec 17, 2021   
    Acromegaly is associated with cardiovascular and endocrinal disorders. Screening for these disorders at the time of diagnosis can lead to early management and better outcomes translating into decreased mortality.
  • ||||||||||  Clinical, Journal:  CLINICALLY NON-FUNCTIONING PITUITARY ADENOMAS. (Pubmed Central) -  Dec 17, 2021   
    NFPA can sometimes recur even after complete resection, but predicting the individual risk of tumor remnant progression is difficult. Postoperative irradiation is only considered in case of residual tumor growth or relapse, due to its potential side effects.
  • ||||||||||  pregabalin / Generic mfg.
    Journal:  Carpal Tunnel Syndrome:Diagnosis and Treatment (Pubmed Central) -  Dec 17, 2021   
    For conservative treatment, a neutral wrist splint worn at night or oral medication such as nonsteroidal anti-inflammatory drugs, vitamin B12, and pregabalin have been shown to be effective against CTS...The surgery involves a small skin incision under a microscope and local anesthesia. Long-term outcomes with respect to pain, numbness, function, symptomatology relapse, and frequency of re-surgery do not significantly differ between patients subjected to open or endoscopic surgery.
  • ||||||||||  Clinical, Journal:  Voice Characteristics in Patients with Acromegaly during Treatment. (Pubmed Central) -  Dec 16, 2021   
    Voice characteristics are in the normal range in patients with acromegaly, but may change during treatment. However, voice complaints are important to discuss, since they may influence quality of life.
  • ||||||||||  Journal:  Female pattern hair loss with acromegaly. (Pubmed Central) -  Dec 16, 2021   
    However, voice complaints are important to discuss, since they may influence quality of life. No abstract available
  • ||||||||||  Journal:  Cardiovascular complications of acromegaly. (Pubmed Central) -  Dec 16, 2021   
    Acromegaly-related cardiac valve abnormalities may be related to fibrotic changes and seem to persist after effective treatment of acromegaly. Advances in acromegaly treatment over the last decades significantly diminished the cardiovascular burden of the disease, with the cardiovascular disease anymore being the leading cause of death.
  • ||||||||||  Metopirone (metyrapone) / HRA Pharma
    Review, Journal:  Prolactin and Other Pituitary Disorders in Kidney Disease. (Pubmed Central) -  Dec 16, 2021   
    However, the hypothalamic-pituitary-adrenal axis is less inhibited by 1 mg dexamethasone but retains normal suppression by higher-dose dexamethasone...Diabetes insipidus can be masked in advanced kidney disease until kidney transplantation. Diagnosis of the syndrome of inappropriate antidiuretic hormone is similar in mild or moderate kidney disease as in normal subjects, but is challenging in patients with advanced kidney disease owing to the impairment in urine dilution.